216 related articles for article (PubMed ID: 27301766)
1. The Business Case for Expanded Clozapine Utilization.
Gören JL; Rose AJ; Smith EG; Ney JP
Psychiatr Serv; 2016 Nov; 67(11):1197-1205. PubMed ID: 27301766
[TBL] [Abstract][Full Text] [Related]
2. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Thomas J; Henderson W; Frisman L; Fye C; Charney D
N Engl J Med; 1997 Sep; 337(12):809-15. PubMed ID: 9295240
[TBL] [Abstract][Full Text] [Related]
3. New vs. old antipsychotics: the Texas experience.
Reid WH
J Clin Psychiatry; 1999; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia.
Meltzer HY; Cola P; Way L; Thompson PA; Bastani B; Davies MA; Snitz B
Am J Psychiatry; 1993 Nov; 150(11):1630-8. PubMed ID: 8105705
[TBL] [Abstract][Full Text] [Related]
5. Organizational Characteristics of Veterans Affairs Clinics With High and Low Utilization of Clozapine.
Gören JL; Rose AJ; Engle RL; Smith EG; Christopher ML; Rickles NM; Semla TP; McCullough MB
Psychiatr Serv; 2016 Nov; 67(11):1189-1196. PubMed ID: 27301765
[TBL] [Abstract][Full Text] [Related]
6. Clozapine for refractory schizophrenia: the Illinois experience.
Buckman RW; Malan RD
J Clin Psychiatry; 1999; 60 Suppl 1():18-22; discussion 28-30. PubMed ID: 10037166
[TBL] [Abstract][Full Text] [Related]
7. [Medico-economic study of Léponex (clozapine) in the Bordeaux Charles Perrens Hospital Center].
Bret P; Jolivel C; Bret MC; Veylit S; Martin C; Garcia P
Encephale; 1998; 24(4):365-77. PubMed ID: 9809242
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Allan E; Erdos J; Frisman LK; Xu W; Thomas J; Henderson W; Charney D
Arch Gen Psychiatry; 1999 Jun; 56(6):565-72. PubMed ID: 10359474
[TBL] [Abstract][Full Text] [Related]
9. Changing environments and alternative perspectives in evaluating the cost-effectiveness of new antipsychotic drugs.
Rosenheck R; Doyle J; Leslie D; Fontana A
Schizophr Bull; 2003; 29(1):81-93. PubMed ID: 12908663
[TBL] [Abstract][Full Text] [Related]
10. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.
Oh PI; Iskedjian M; Addis A; Lanctôt K; Einarson TR
Can J Clin Pharmacol; 2001; 8(4):199-206. PubMed ID: 11743592
[TBL] [Abstract][Full Text] [Related]
11. Clozapine: current status and role in the pharmacotherapy of schizophrenia.
Remington GJ; Addington D; Collins EJ; Jones BD; Lalonde P; MacCrimmon DJ; MacEwan GW
Can J Psychiatry; 1996 Apr; 41(3):161-6. PubMed ID: 8722645
[TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of clozapine: a controlled, population-based, mirror-image study.
Hayhurst KP; Brown P; Lewis SW
J Psychopharmacol; 2002 Jun; 16(2):169-75. PubMed ID: 12095076
[TBL] [Abstract][Full Text] [Related]
13. Initiating clozapine treatment in the outpatient clinic: service utilization and cost trends.
Luchins DJ; Hanrahan P; Shinderman M; Lagios L; Fichtner CG
Psychiatr Serv; 1998 Aug; 49(8):1034-8. PubMed ID: 9712208
[TBL] [Abstract][Full Text] [Related]
14. Cost-benefit analysis of risperidone and clozapine in the treatment of schizophrenia in Israel.
Ginsberg G; Shani S; Lev B
Pharmacoeconomics; 1998 Feb; 13(2):231-41. PubMed ID: 10178649
[TBL] [Abstract][Full Text] [Related]
15. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec.
Latimer E; Wynant W; Clark R; Malla A; Moodie E; Tamblyn R; Naidu A
Clin Schizophr Relat Psychoses; 2013 Apr; 7(1):33-41. PubMed ID: 23367500
[TBL] [Abstract][Full Text] [Related]
16. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.
Rosenheck R; Cramer J; Xu W; Grabowski J; Douyon R; Thomas J; Henderson W; Charney D
Health Serv Res; 1998 Dec; 33(5 Pt 1):1237-61. PubMed ID: 9865219
[TBL] [Abstract][Full Text] [Related]
17. Generic replacement of clozapine: a simple decision model from a Canadian perspective.
Layton S; Barbeau M
Curr Med Res Opin; 2004 Apr; 20(4):453-9. PubMed ID: 15119982
[TBL] [Abstract][Full Text] [Related]
18. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.
Duggan A; Warner J; Knapp M; Kerwin R
Br J Psychiatry; 2003 Jun; 182():505-8. PubMed ID: 12777341
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
20. [Medico-economic evaluation of treatment with clozapine versus treatment with previous neuroleptics].
Geronimi-Ferret D; Lesay M; Barges-Bertocchio MH; Cornet-Bonnefont M; Robert H
Encephale; 1997 Sep; 23 Spec No 4():24-31. PubMed ID: 9417402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
